COVID-19 vaccines will go through the rigours of Phase 3 randomized clinical trial evaluations. They will have to meet regulatory standards for safety and efficacy. But there is a possibility that we will not detect extremely rare side-effects in Phase 3 trials.
The new head of Ontario’s ‘super agency’ discusses the pandemic, and how the new organization hopes to improve the work experience of healthcare providers.
